2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: Executive summary

A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society

Writing Committee Members*

Win-Kuang Shen, MD, FACC, FAHA, FHRS (Chair), † Robert S. Sheldon, MD, PhD, FHRS (Vice Chair), David G. Benditt, MD, FACC, FHRS,‡ Mitchell I. Cohen, MD, FACC, FHRS,‡ Daniel E. Forman, MD, FACC, FAHA,‡ Zachary D. Goldberger, MD, MS, FACC, FAHA, FHRS,‡ Blair P. Grubb, MD, FACC,¶ Mohamed H. Hamdan, MD, MBA, FACC, FHRS,¶ Andrew D. Krahn, MD, FHRS,¶ Mark S. Link, MD, FACC,¶ Brian Olshansky, MD, FACC, FAHA, FHRS,¶ Satish R. Raj, MD, MSc, FACC, FHRS,¶ Roopinder Kaur Sandhu, MD, MPH,¶ Dan Sorajja, MD,¶ Benjamin C. Sun, MD, MPP, FACEP,¶ Clyde W. Yancy, MD, MSc, FACC, FAHA

ACC/AHA Task Force Members

Glenn N. Levine, MD, FACC, FAHA, Chair
Patrick T. O’Gara, MD, FACC, FAHA, Chair-Elect
Jonathan L. Halperin, MD, FACC, FAHA, Immediate Past Chair#
Sana M. Al-Khatib, MD, MHS, FACC, FAHA
Kim K. Bircher, MS, PharmD, AACC
Biykem Bozkurt, MD, PhD, FACC, FAHA
Ralph G. Brindis, MD, MPH, MACC#
Joaquin E. Cigarroa, MD, FACC
Lesley H. Curtis, PhD, FAHA
Lee A. Fleischer, MD, FACC, FAHA
Federico Gentile, MD, FACC
Samuel Gidding, MD, FAHA
Mark A. Hlatky, MD, FACC
John Ikonomidis, MD, PhD, FAHA
José Joglar, MD, FACC, FAHA
Susan J. Pressler, PhD, RN, FAHA
Duminda N. Wijeysundera, MD, PhD

*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1 for detailed information.

†ACC/AHA Task Force on Clinical Practice Guidelines Liaison.
‡ACC/AHA Representative.
¶HRS Representative.
§ACEP and SAEM Joint Representative.
#ACC/AHA Task Force on Performance Measures Liaison.
*Former Task Force member; current member during the writing effort.

KEYWORDS

ACC/AHA clinical practice guidelines; Syncope; Risk assessment; Diagnosis; Prognosis; Cardiac syncope; Reflex syncope; Vasovagal syncope; Orthostatic hypotension; Neurogenic syncope; Dehydration; Pediatrics; Adult congenital heart disease; Geriatrics; Driving; Athletes (Heart Rhythm 2017;14:e218–e254)

Developed in collaboration with the American College of Emergency Physicians and Society for Academic Emergency Medicine. Endorsed by the Pediatric and Congenital Electrophysiology Society. This document was approved by the American College of Cardiology Clinical Policy Approval Committee on behalf of the Board of Trustees, the American Heart Association Science Advisory and Coordinating Committee, the American Heart Association Executive Committee, and the Heart Rhythm Society Board of Trustees in January 2017. The Heart Rhythm Society requests that this document be cited as follows: Shen W-K, Sheldon RS, Benditt DG, Cohen MI, Forman DE, Goldberger ZD, Grubb BP, Hamdan MH, Krahn AD, Link MS, Olshansky B, Raj SR, Sandhu RK, Sorajja D, Sun BC, Yancy CW. 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2017;14:e218–e254. This article has been copublished in Circulation and Journal of the American College of Cardiology. Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.acc.org), the American Heart Association (professional.heart.org), and the Heart Rhythm Society (www.hrsonline.org). For copies of this document, please contact the Elsevier Inc. Reprint Department (reprints@elsevier.com). Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the Heart Rhythm Society. Instructions for obtaining permission are located at https://www.elsevier.com/about/our-business/policies/copyright/permissions.

http://dx.doi.org/10.1016/j.hrthm.2017.03.005

1547-5271/see front matter © 2017 American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society.
# TABLE OF CONTENTS

Preamble .............................................................................. e219
1. Introduction ................................................................. e221
   1.1. Methodology and Evidence Review ................ e221
   1.2. Organization of the Writing Committee .......... e222
   1.3. Document Review and Approval .................. e222
   1.4. Scope of the Guideline ................................. e222
2. General Principles ...................................................... e222
   2.1. Definitions: Terms and Classification .......... e223
   2.2. Epidemiology and Demographics ................. e224
3. Initial Evaluation of Patients With Syncope: Recommendations ............................ e225
   3.1. History and Physical Examination ............... e225
   3.2. Cardiovascular Testing: Recommendations .... e228
      3.2.1. Cardiac Imaging .................................. e228
      3.2.2. Stress Testing ..................................... e229
      3.2.3. Cardiac Monitoring .............................. e229
      3.2.4. In-Hospital Telemetry .......................... e230
      3.2.5. Electrophysiological Study ................... e230
      3.2.6. Tilt-Table Testing .............................. e230
      3.3. Neurological Testing: Recommendations .... e231
      3.3.1. Autonomic Evaluation .......................... e231
      3.3.2. Neurological and Imaging Diagnostics ...... e231
4. Arrhythmic Conditions: Recommendations .................................. e231
   4.1. Bradycardia .................................................. e231
      4.1.1. Supraventricular Tachycardia ................. e231
      4.1.2. Ventricular Arrhythmia ........................ e231
   4.2. Structural Conditions: Recommendations .......... e231
      4.2.1. Ischemic and Nonischemic Cardiomyopathy .. e231
      4.2.2. Valvular Heart Disease ......................... e231
      4.2.3. Hypertrophic Cardiomyopathy ........................ e231
      4.2.4. Arrhythmogenic Right Ventricular Cardiomyopathy .................................. e232
      4.2.5. Cardiac Sarcoidosis ................................. e232
   4.3. Inheritable Arrhythmic Conditions: Recommendations .................................. e232
      4.3.1. Brugada Syndrome ................................. e232
      4.3.2. Short-QT Syndrome ............................... e232
      4.3.3. Long-QT Syndrome ............................... e232
      4.3.4. Catecholaminergic Polymorphic Ventricular Tachycardia .................................. e232
      4.3.5. Early Repolarization Pattern ...................... e233
5. Reflex Conditions: Recommendations .................................. e233
   5.1. Vasovagal Syncope .......................................... e233
   5.2. Pacemakers in Vasovagal Syncope ................ e234
   5.3. Carotid Sinus Syndrome ................................. e234
   5.4. Other Reflex Conditions ................................. e234
6. Orthostatic Hypotension: Recommendations .......... e234
   6.1. Neurogenic Orthostatic Hypotension ................. e234
   6.2. Dehydration and Drugs .................................... e235
7. Orthostatic Intolerance .............................................. e235
8. Pseudosyncope: Recommendations ................................. e236
9. Uncommon Conditions Associated With Syncope ..... e236
10. Age, Lifestyle, and Special Populations: Recommendations .................................. e236
   10.1. Pediatric Syncope ......................................... e236
   10.2. Adult Congenital Heart Disease ..................... e236
   10.3. Geriatric Patients ....................................... e236
   10.4. Driving and Syncope .................................... e237
   10.5. Athletes .................................................. e237
11. Quality of Life and Healthcare Cost of Syncope ... e238
   11.1. Impact of Syncope on Quality of Life ........... e238
   11.2. Healthcare Costs Associated With Syncope ..... e238
12. Emerging Technology, Evidence Gaps, and Future Directions .................................. e238
   12.1. Definition, Classification, and Epidemiology .. e238
   12.2. Risk Stratification and Clinical Outcomes .... e238
   12.3. Evaluation and Diagnosis ............................ e238
   12.4. Management of Specific Conditions .......... e238
   12.5. Special Populations .................................... e238
References ..................................................................... e239
Appendix 1  
   Author Relationships With Industry and Other Entities (Relevant) .................. e247
Appendix 2  
   Reviewer Relationships With Industry and Other Entities (Comprehensive) .......... e249
Appendix 3  
   Abbreviations ..................................................... e254

---

# Preamble

Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines (guidelines) with recommendations to improve cardiovascular health. These guidelines, which are based on systematic methods to evaluate and classify evidence, provide a cornerstone for quality cardiovascular care. The ACC and AHA sponsor the development and publication of guidelines without commercial support, and members of each organization volunteer their time to the writing and review efforts. Guidelines are official policy of the ACC and AHA.

# Intended Use

Practice guidelines provide recommendations applicable to patients with or at risk of developing cardiovascular disease. The focus is on medical practice in the United States, but guidelines developed in collaboration with other organizations may have a global impact. Although guidelines may be used to inform regulatory or payer decisions, their intent is to improve patients’ quality of care and align with patients’ interests. Guidelines are intended to define practices meeting the needs of patients in most, but not all, circumstances and should not replace clinical judgment.

# Clinical Implementation

Guideline-recommended management is effective only when followed by healthcare providers and patients. Adherence to
recommendations can be enhanced by shared decision making between healthcare providers and patients, with patient engagement in selecting interventions based on individual values, preferences, and associated conditions and comorbidities.

**Methodology and Modernization**

The ACC/AHA Task Force on Clinical Practice Guidelines (Task Force) continuously reviews, updates, and modifies guideline methodology on the basis of published standards from organizations including the Institute of Medicine and on the basis of internal reevaluation. Similarly, the presentation and delivery of guidelines are reevaluated and modified on the basis of evolving technologies and other factors to facilitate optimal dissemination of information at the point of care to healthcare professionals. Given time constraints of busy healthcare providers and the need to limit text, the current guideline format delineates that each recommendation be supported by limited text (ideally, <250 words) and hyperlinks to supportive evidence summary tables. Ongoing efforts to further limit text are underway. Recognizing the importance of cost–value considerations in certain guidelines, when appropriate and feasible, an analysis of the value of a drug, device, or intervention may be performed in accordance with the ACC/AHA methodology.

To ensure that guideline recommendations remain current, new data are reviewed on an ongoing basis, with full guideline revisions commissioned in approximately 6-year cycles. Publication of new, potentially practice-changing study results that are relevant to an existing or new drug, device, or management strategy will prompt evaluation by the Task Force, in consultation with the relevant guideline writing committee, to determine whether a focused update should be commissioned. For additional information and policies regarding guideline development, we encourage readers to consult the ACC/AHA guideline methodology manual and other methodology articles.

**Selection of Writing Committee Members**

The Task Force strives to avoid bias by selecting experts from a broad array of backgrounds. Writing committee members represent different geographic regions, sexes, ethnicities, races, intellectual perspectives/biases, and scopes of clinical practice. The Task Force may also invite organizations and professional societies with related interests and expertise to participate as partners, collaborators, or endorsers.

**Relationships With Industry and Other Entities**

The ACC and AHA have rigorous policies and methods to ensure that guidelines are developed without bias or improper influence. The complete relationships with industry and other entities (RWI) policy can be found online. Appendix 1 of the current document lists writing committee members’ relevant RWI. For the purposes of full transparency, writing committee members’ comprehensive disclosure information is available online, as is comprehensive disclosure information for the Task Force.

**Evidence Review and Evidence Review Committees**

When developing recommendations, the writing committee uses evidence-based methodologies that are based on all available data. Literature searches focus on randomized controlled trials (RCTs) but also include registries, nonrandomized comparative and descriptive studies, case series, cohort studies, systematic reviews, and expert opinion. Only key references are cited.

An independent evidence review committee (ERC) is commissioned when there are 1 or more questions deemed of utmost clinical importance that merit formal systematic review. This systematic review will determine which patients are most likely to benefit from a drug, device, or treatment strategy and to what degree. Criteria for commissioning an ERC and formal systematic review include: a) the absence of a current authoritative systematic review; b) the feasibility of defining the benefit and risk in a time frame consistent with the writing of a guideline; c) the relevance to a substantial number of patients; and d) the likelihood that the findings can be translated into actionable recommendations. ERC members may include methodologists, epidemiologists, healthcare providers, and biostatisticians. The recommendations developed by the writing committee on the basis of the systematic review are marked with "SR".

**Guideline-Directed Management and Therapy**

The term guideline-directed management and therapy (GDMT) encompasses clinical evaluation, diagnostic testing, and pharmacological and procedural treatments. For these and all recommended drug treatment regimens, the reader should confirm the dosage by reviewing product insert material and evaluate the treatment regimen for contraindications and interactions. The recommendations are limited to drugs, devices, and treatments approved for clinical use in the United States.

**Class of Recommendation and Level of Evidence**

The Class of Recommendation (COR) indicates the strength of the recommendation, encompassing the estimated magnitude and certainty of benefit in proportion to risk. The Level of Evidence (LOE) rates the quality of scientific evidence that supports the intervention on the basis of the type, quantity, and consistency of data from clinical trials and other sources (Table 1). The reader is encouraged to consult the full-text guideline for additional guidance and details with regard to syncope because this executive summary contains limited information.

Glenn N. Levine, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Clinical Practice Guidelines
1. Introduction

1.1. Methodology and Evidence Review

The recommendations listed in this guideline are, whenever possible, evidence based. An initial extensive evidence review, which included literature derived from research involving human subjects, published in English, and indexed in MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline, was conducted from July to October 2015. Key search words included but were not limited to the following: athletes, autonomic neuropathy, bradycardia, carotid sinus hypersensitivity, carotid sinus syndrome, children, death, dehydration, diagnosis, driving, electrocardiogram, electrophysiological study, epidemiology, falls, implantable loop recorder, mortality, older populations, orthostatic hypotension, pediatrics, psychogenic pseudosyncope, recurrent syncope, risk stratification, supraventricular tachycardia, syncope unit, syncope, tilt-table test, vasovagal

---

**Table 1** Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care* (Updated August 2015)

<table>
<thead>
<tr>
<th>CLASS (STRENGTH) OF RECOMMENDATION</th>
<th>LEVEL (QUALITY) OF EVIDENCE†</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CLASS I (STRONG)</strong> Benefit &gt;&gt; Risk</td>
<td><strong>LEVEL A</strong></td>
</tr>
<tr>
<td>Suggested phrases for writing recommendations:</td>
<td></td>
</tr>
<tr>
<td>• Is recommended</td>
<td>- High-quality evidence† from more than 1 RCT</td>
</tr>
<tr>
<td>• Is indicated/useful/effective/beneficial</td>
<td>- Meta-analyses of high-quality RCTs</td>
</tr>
<tr>
<td>• Should be performed/administered/other</td>
<td>- One or more RCTs corroborated by high-quality registry studies</td>
</tr>
<tr>
<td>• Comparative-Effectiveness Phrases‡:</td>
<td></td>
</tr>
<tr>
<td>o Treatment/strategy A is recommended/directed in preference to treatment B</td>
<td></td>
</tr>
<tr>
<td>o Treatment A should be chosen over treatment B</td>
<td></td>
</tr>
<tr>
<td><strong>CLASS IIa (MODERATE)</strong> Benefit &gt;&gt; Risk</td>
<td><strong>LEVEL B-R</strong> (Randomized)</td>
</tr>
<tr>
<td>Suggested phrases for writing recommendations:</td>
<td></td>
</tr>
<tr>
<td>• Is reasonable</td>
<td>- Moderate-quality evidence† from 1 or more RCTs</td>
</tr>
<tr>
<td>• Can be useful/effective/beneficial</td>
<td>- Meta-analyses of moderate-quality RCTs</td>
</tr>
<tr>
<td>• Comparative-Effectiveness Phrases‡:</td>
<td></td>
</tr>
<tr>
<td>o Treatment/strategy A is probably recommended/directed in preference to treatment B</td>
<td></td>
</tr>
<tr>
<td>o It is reasonable to choose treatment A over treatment B</td>
<td></td>
</tr>
<tr>
<td><strong>CLASS IIb (WEAK)</strong> Benefit ≥ Risk</td>
<td><strong>LEVEL B-NR</strong> (Nonrandomized)</td>
</tr>
<tr>
<td>Suggested phrases for writing recommendations:</td>
<td></td>
</tr>
<tr>
<td>• May/might be reasonable</td>
<td>- Moderate-quality evidence† from 1 or more well-designed, well-executed nonrandomized studies, observational studies, or registry studies</td>
</tr>
<tr>
<td>• May/might be considered</td>
<td>- Meta-analyses of such studies</td>
</tr>
<tr>
<td>• Usefulness/effectiveness is unknown/unclear/uncertain or not well established</td>
<td>- Physiological or mechanistic studies in human subjects</td>
</tr>
<tr>
<td><strong>CLASS III: No Benefit (MODERATE)</strong> Benefit = Risk</td>
<td><strong>LEVEL C-LD</strong> (Limited Data)</td>
</tr>
<tr>
<td>(Generally, LOE A or B use only)</td>
<td></td>
</tr>
<tr>
<td>Suggested phrases for writing recommendations:</td>
<td></td>
</tr>
<tr>
<td>• Is not recommended</td>
<td>- Randomized or nonrandomized observational or registry studies with limitations of design or execution</td>
</tr>
<tr>
<td>• Is not indicated/useful/effective/beneficial</td>
<td>- Meta-analyses of such studies</td>
</tr>
<tr>
<td>• Should not be performed/administered/other</td>
<td>- Physiological or mechanistic studies in human subjects</td>
</tr>
<tr>
<td><strong>CLASS III: Harm (STRONG)</strong> Risk &gt; Benefit</td>
<td><strong>LEVEL C-EO</strong> (Expert Opinion)</td>
</tr>
<tr>
<td>Suggested phrases for writing recommendations:</td>
<td></td>
</tr>
<tr>
<td>• Potentially harmful</td>
<td>Consensus of expert opinion based on clinical experience</td>
</tr>
<tr>
<td>• Causes harm</td>
<td></td>
</tr>
<tr>
<td>• Associated with excess morbidity/mortality</td>
<td></td>
</tr>
<tr>
<td>• Should not be performed/administered/other</td>
<td></td>
</tr>
</tbody>
</table>

* The outcome or result of the intervention should be specified (an improved clinical outcome or increased diagnostic accuracy or incremental prognostic information).
† For comparative-effectiveness recommendations (COR I and IIa; LOE A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.
‡ The method of assessing quality is evolving, including the application of standardized, widely used, and preferably validated evidence grading tools; and for systematic reviews, the incorporation of an Evidence Review Committee.

COR indicates Class of Recommendation; EO, expert opinion; LD, limited data; LOE, Level of Evidence; NR, nonrandomized; R, randomized; and RCT, randomized controlled trial.

COR and LOE are determined independently (any COR may be paired with any LOE).
syncope, and ventricular arrhythmia. Additional relevant studies published through October 2016, during the guideline writing process, were also considered by the writing committee, and added to the evidence tables when appropriate. The finalized evidence tables, included in the Online Data Supplement, summarize the evidence used by the writing committee to formulate recommendations. Lastly, the writing committee reviewed documents related to syncope previously published by the ACC and AHA and other organizations and societies. References selected and published in this document are representative and not all inclusive.

An independent ERC was commissioned to perform a systematic review of clinical questions, the results of which were considered by the writing committee for incorporation into this guideline. The systematic review report “Pacing as a Treatment for Reflex-Mediated (Vasovagal, Situational, or Carotid Sinus Hypersensitivity) Syncope” is published in conjunction with this guideline.10

1.2. Organization of the Writing Committee
The writing committee was composed of clinicians with expertise in caring for patients with syncope, including cardiologists, electrophysiologists, an emergency physician, and a pediatric cardiologist. The writing committee included representatives from the ACC, AHA, Heart Rhythm Society (HRS), American Academy of Neurology, American College of Emergency Physicians, and Society for Academic Emergency Medicine.

1.3. Document Review and Approval
This document was reviewed by 2 official reviewers each nominated by the ACC, AHA, and HRS; 1 reviewer each from the American Academy of Neurology, American College of Emergency Physicians and Society for Academic Emergency Medicine, and Pediatric and Congenital Electrophysiology Society; a lay/patient representative; and 25 individual content reviewers. Reviewers’ RWI information was distributed to the writing committee and is published in this document (Appendix 2).

This document was approved for publication by the governing bodies of the ACC, AHA, and HRS and endorsed by the American College of Emergency Physicians, Society for Academic Emergency Medicine, and the Pediatric and Congenital Electrophysiology Society.

1.4. Scope of the Guideline
The purpose of this ACC/AHA/HRS guideline is to provide contemporary, accessible, and succinct guidance on the management of adult and pediatric patients with suspected syncope. This guideline is intended to be a practical document for cardiologists, arrhythmia specialists, neurologists, emergency physicians, general internists, geriatric specialists, sports medicine specialists, and other healthcare professionals involved in the care of this very large and heterogeneous population. It is not a review of physiology, pathophysiology, or mechanisms of underlying conditions associated with syncope. The nature of syncope as a symptom required that the writing committee consider numerous conditions for which it can be a symptom, and as much as possible, we have addressed the involvement of syncope only as a presenting symptom. Because of the plausible association of syncope and sudden cardiac death (SCD) in selected populations, this document discusses risk stratification and prevention of SCD when appropriate. The use of the terms selected populations and selected patients in this document is intended to direct healthcare providers to exercise clinical judgment, which is often required during the evaluation and management of patients with syncope. When a recommendation is made to refer a patient to a specialist with expertise for further evaluation, such as in the case of autonomic neurology, adult congenital heart disease (ACHD), older populations, or athletes, the writing committee agreed to make Class IIa recommendations because of the paucity of outcome data. The definition of older populations has been evolving. Age >75 years is used to define older populations or older adults in this document, unless otherwise specified. If a study has defined older adults by a different age cutoff, the relevant age is noted in those specific cases. Finally, the guideline addresses the management of syncope with the patient as a focus, rather than larger aspects of health services, such as syncope management units. The goals of the present guideline are:

- To define syncope as a symptom, with different causes, in different populations and circumstances.
- To provide guidance and recommendations on the evaluation and management of patients with suspected syncope in the context of different clinical settings, specific causes, or selected circumstances.
- To identify key areas in which knowledge is lacking, to foster future collaborative research opportunities and efforts.

In developing this guideline, the writing committee reviewed the evidence to support recommendations in the relevant ACC/AHA guidelines noted in Table 2 (in the full-text guideline) and affirms the ongoing validity of the related recommendations in the context of syncope, thus obviating the need to repeat existing guideline recommendations in the present guideline when applicable or when appropriate.

2. General Principles
For the purpose of this guideline, definitions of syncope and relevant terms are provided in Table 2. See Table 3 for historical characteristics associated with, although not diagnostic, cardiac and noncardiac syncope; Table 4 for short- and long-term risk factors; Table 5 for the type of events, event rates, and study durations from investigations that estimate risk scores; Table 6 for examples of serious conditions associated with syncope which may require inpatient evaluation and “treatment”; Figure 1 for the algorithm on initial evaluation for syncope; and Figure 2 for patient disposition after initial evaluation for syncope. See Online Data Supplements 1 through 4 for data supporting Section 2.
### 2.1. Definitions: Terms and Classification

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition/Comments and References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Syncope</td>
<td>A symptom that presents with an abrupt, transient, complete loss of consciousness, associated with inability to maintain postural tone, with rapid and spontaneous recovery. The presumed mechanism is cerebral hypoperfusion. There should not be clinical features of other nonsyncope causes of loss of consciousness, such as seizure, antecedent head trauma, or apparent loss of consciousness (i.e., pseudosyncope).</td>
</tr>
<tr>
<td>Loss of consciousness</td>
<td>A cognitive state in which one lacks awareness of oneself and one’s situation, with an inability to respond to stimuli.</td>
</tr>
<tr>
<td>Orthostatic intolerance</td>
<td>A syndrome consisting of a constellation of symptoms that include frequent, recurrent, or unexplained syncope, orthostatic tachycardia, and/or presyncope. Carotid sinus syndrome is due to dysfunction of the autonomic nervous system and not solely due to lesions involving the central or peripheral autonomic nerves.</td>
</tr>
<tr>
<td>Unexplained syncope (syncope of undetermined etiology)</td>
<td>Syncope for which a cause is undetermined after an initial evaluation that is deemed appropriate by the experienced healthcare provider. The initial evaluation includes but is not limited to a thorough history, physical examination, and ECG.</td>
</tr>
<tr>
<td>Orthostatic tachycardia</td>
<td>A sustained increase in heart rate of 40 bpm in individuals 12–19 y of age.</td>
</tr>
<tr>
<td>Orthostatic hypotension (OH)</td>
<td>A drop in systolic BP of ≥20 mm Hg or diastolic BP of ≥10 mm Hg with assumption of an upright posture.</td>
</tr>
<tr>
<td>• Initial (immediate) OH</td>
<td>A transient BP decrease within 15 s after standing, with presyncope or syncope.</td>
</tr>
<tr>
<td>• Classic OH</td>
<td>A sustained reduction of systolic BP of ≥20 mm Hg or diastolic BP of ≥10 mm Hg within 3 min of assuming upright posture.</td>
</tr>
<tr>
<td>• Delayed OH</td>
<td>A sustained reduction of systolic BP of ≥20 mm Hg (or 30 mm Hg in patients with supine hypertension) or diastolic BP of ≥10 mm Hg that takes &gt;3 min of upright posture to develop. The fall in BP is usually gradual until reaching the threshold.</td>
</tr>
<tr>
<td>• Neurogenic OH</td>
<td>A subtype of OH that is due to dysfunction of the autonomic nervous system and not solely due to environmental triggers (such as dehydration or drugs). Neurogenic OH is due to lesions involving the central or peripheral autonomic nerves.</td>
</tr>
<tr>
<td>Cardiac (cardiovascular) syncope</td>
<td>Syncope caused by bradycardia, tachycardia, or hypotension due to low cardiac index, blood flow obstruction, vasodilatation, or acute vascular dissection.</td>
</tr>
<tr>
<td>Noncardiac syncope</td>
<td>Syncope due to noncardiac causes, which includes reflex syncope, OH, volume depletion, dehydration, and blood loss.</td>
</tr>
<tr>
<td>Reflex (neurally mediated) syncope</td>
<td>Syncope due to a reflex that causes vasodilation, bradycardia, or both.</td>
</tr>
<tr>
<td>• Vasovagal syncope (VVS)</td>
<td>The most common form of reflex syncope mediated by the vasovagal reflex. VVS: 1) may occur with upright posture (standing or seated or with exposure to emotional stress, pain, or medical settings); 2) typically is characterized by diaphoresis, warmth, nausea, and pallor; 3) is associated with vasodepressor hypotension and/or inappropriate bradycardia; and 4) is often followed by fatigue. Typical features may be absent in older patients. VVS is often preceded by identifiable triggers and/or by a characteristic prodrome. The diagnosis is made primarily on the basis of a thorough history, physical examination, and eyewitness observation, if available.</td>
</tr>
<tr>
<td>• Carotid sinus syndrome</td>
<td>Reflex syncope associated with carotid sinus hypersensitivity. Carotid sinus hypersensitivity is present when a pause ≥3 s and/or a decrease of systolic pressure ≥50 mm Hg occurs upon stimulation of the carotid sinus. It occurs more frequently in older patients. Carotid sinus hypersensitivity can be associated with varying degrees of symptoms. Carotid sinus syndrome is defined when syncope occurs in the presence of carotid sinus hypersensitivity.</td>
</tr>
</tbody>
</table>
2.2. Epidemiology and Demographics

Studies of syncope report prevalence rates as high as 41%, with recurrent syncope occurring in 13.5%. In a cross section of 1,925 randomly selected residents of Olmsted County, Minnesota, with a median age of 62 years (all age >45 years), 364 reported an episode of syncope in their lifetime;

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition/Comments and References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Situational syncope</td>
<td>Reflex syncope associated with a specific action, such as coughing, laughing, swallowing, micturition, or defecation. These syncope events are closely associated with specific physical functions.</td>
</tr>
<tr>
<td>Postural (orthostatic) tachycardia syndrome (POTS)</td>
<td>A clinical syndrome usually characterized by all of the following: 1) frequent symptoms that occur with standing (e.g., lightheadedness, palpitations, tremulousness, generalized weakness, blurred vision, exercise intolerance, and fatigue); and 2) an increase in heart rate of &gt;30 bpm during a positional change from supine to standing (or ≥40 bpm in those 12–19 y of age); and 3) the absence of OH (&gt;20 mm Hg reduction in systolic BP). Symptoms associated with POTS include those that occur with standing (e.g., lightheadedness, palpitations); those not associated with particular postures (e.g., bloating, nausea, diarrhea, abdominal pain); and those that are systemic (e.g., fatigue, sleep disturbance, migraine headaches). The standing heart rate is often &gt;120 bpm.</td>
</tr>
<tr>
<td>Psychogenic pseudosyncope</td>
<td>A syndrome of apparent but not true loss of consciousness that may occur in the absence of identifiable cardiac, reflex, neurological, or metabolic causes.</td>
</tr>
</tbody>
</table>

BP indicates blood pressure; ECG, electrocardiogram; OH, orthostatic hypotension; POTS, postural tachycardia syndrome; and VVS, vasovagal syncope.

*These definitions are derived from previously published definitions from scientific investigations, guidelines, expert consensus statements, and Webster dictionary after obtaining consensus from the WC.

Figure 1  Syncope Initial Evaluation.

*See relevant terms and definitions in Table 2.

Colors correspond to Class of Recommendation in Table 1. This figure shows the general principles for initial evaluation of all patients after an episode of syncope. ECG indicates electrocardiogram.
the estimated prevalence of syncope was 19%. Females reported a higher prevalence of syncope (22% versus 15%, p<0.001).26 The incidence follows a trimodal distribution in both sexes, with the first episode common around 20, 60, or 80 years of age and the third peak occurring 5 to 7 years earlier in males.27 Predictors of recurrent syncope in older adults are aortic stenosis, impaired renal function, atrioventricular or left bundle-branch block, male sex, chronic obstructive pulmonary disorder, heart failure, atrial fibrillation, advancing age, and orthostatic medications,27 with a sharp increase in incidence after 70 years of age.17 Reflex syncope was most common (21%), followed by cardiac syncope (9%) and OH (9%), with the cause of syncope unknown in 37%.17 In patients with New York Heart Association class III–IV heart failure, syncope is present in 12% to 14% of patients.28,29

In older adults, there is a greater risk of hospitalization and death related to syncope. The National Hospital Ambulatory Medical Care Survey reported 6.7 million episodes of syncope in the emergency department, or 0.77% of all ED patients. Among patients >80 years of age, 58% were admitted to hospital.30 The prevalence of syncope as a presenting symptom to the ED ranged from 0.8% to 2.4% in multiple studies in both academic and community settings.31–37

### 2.3. Initial Evaluation of Patients With Syncope: Recommendations

#### 2.3.1. History and Physical Examination: Recommendation

<table>
<thead>
<tr>
<th>Recommendation for History and Physical Examination</th>
</tr>
</thead>
<tbody>
<tr>
<td>COR</td>
</tr>
<tr>
<td>I</td>
</tr>
</tbody>
</table>

#### 2.3.2. Electrocardiography: Recommendation

<table>
<thead>
<tr>
<th>Recommendation for Electrocardiography</th>
</tr>
</thead>
<tbody>
<tr>
<td>COR</td>
</tr>
<tr>
<td>I</td>
</tr>
</tbody>
</table>

#### 2.3.3. Risk Assessment: Recommendations

<table>
<thead>
<tr>
<th>Recommendations for Risk Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>COR</td>
</tr>
<tr>
<td>I</td>
</tr>
<tr>
<td>IIb</td>
</tr>
</tbody>
</table>

### Table 3 Historical Characteristics Associated With Increased Probability of Cardiac and Noncardiac Causes of Syncope40,47-55

<table>
<thead>
<tr>
<th>More Often Associated With Cardiac Causes of Syncope</th>
</tr>
</thead>
<tbody>
<tr>
<td>Older age (&gt;60 y)</td>
</tr>
<tr>
<td>Male sex</td>
</tr>
<tr>
<td>Presence of known ischemic heart disease, structural heart disease, previous arrhythmias, or reduced ventricular function</td>
</tr>
<tr>
<td>Brief prodrome, such as palpitations, or sudden loss of consciousness without prodrome</td>
</tr>
<tr>
<td>Syncope during exertion</td>
</tr>
<tr>
<td>Syncope in the supine position</td>
</tr>
<tr>
<td>Low number of syncope episodes (1 or 2)</td>
</tr>
<tr>
<td>Abnormal cardiac examination</td>
</tr>
<tr>
<td>Family history of inheritable conditions or premature SCD (&lt;50 y of age)</td>
</tr>
<tr>
<td>Presence of known congenital heart disease</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>More Often Associated With Noncardiac Causes of Syncope</th>
</tr>
</thead>
<tbody>
<tr>
<td>Younger age</td>
</tr>
<tr>
<td>No known cardiac disease</td>
</tr>
<tr>
<td>Syncope only in the standing position</td>
</tr>
<tr>
<td>Positional change from supine or sitting to standing</td>
</tr>
<tr>
<td>Presence of prodrome: nausea, vomiting, feeling warmth</td>
</tr>
<tr>
<td>Presence of specific triggers: dehydration, pain, distressful stimulus, medical environment</td>
</tr>
<tr>
<td>Situational triggers: cough, laugh, micturition, defecation, deglutition</td>
</tr>
<tr>
<td>Frequent recurrence and prolonged history of syncope with similar characteristics</td>
</tr>
</tbody>
</table>

SCD indicates sudden cardiac death.
Table 4  Short- and Long-Term Risk Factors

<table>
<thead>
<tr>
<th>Short-Term Risk Factors (≤30 d)</th>
<th>Long-Term Risk Factors (&gt;30 d)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>History: Outpatient Clinic or ED Evaluation</strong></td>
<td><strong>Male sex</strong>34,62,64</td>
</tr>
<tr>
<td>Male sex</td>
<td>**Older age (≥60 y)**66</td>
</tr>
<tr>
<td>Older age</td>
<td>No prodrome68</td>
</tr>
<tr>
<td>No prodrome</td>
<td>Palpitations preceding loss of consciousness58</td>
</tr>
<tr>
<td>Palpitations preceding loss of consciousness</td>
<td>Exertional syncope58</td>
</tr>
<tr>
<td>Exertional syncope</td>
<td>Structural heart disease50,58,62,66,68</td>
</tr>
<tr>
<td>Structural heart disease</td>
<td>HF54,58,64,66</td>
</tr>
<tr>
<td>HF</td>
<td>Cerebrovascular disease50</td>
</tr>
<tr>
<td>Cerebrovascular disease</td>
<td>Family history of SCD50</td>
</tr>
<tr>
<td>Family history of SCD</td>
<td>Trauma48,62</td>
</tr>
<tr>
<td>Trauma</td>
<td><strong>Physical Examination or Laboratory Investigation</strong></td>
</tr>
<tr>
<td>Evidence of bleeding58</td>
<td>Positive troponin65</td>
</tr>
<tr>
<td>Persistent abnormal vital signs50</td>
<td>Abnormal ECG65,57,71</td>
</tr>
<tr>
<td>Abnormal ECG</td>
<td>CHADS-2 indicates congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and stroke or transient ischemic attack; ECG, electrocardiogram; ED, emergency department; GFR, glomerular filtration rate; HF, heart failure; SCD, sudden cardiac death; and VA, ventricular arrhythmias.</td>
</tr>
<tr>
<td>Positive troponin</td>
<td></td>
</tr>
</tbody>
</table>

CHADS-2 indicates congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and stroke or transient ischemic attack; ECG, electrocardiogram; ED, emergency department; GFR, glomerular filtration rate; HF, heart failure; SCD, sudden cardiac death; and VA, ventricular arrhythmias.

*Definitions for clinical endpoints or serious outcomes vary by study. The specific endpoints for the individual studies in this table are defined in Data Supplements 3 and 4 and summarized in Table 5 for selected studies. This table includes individual risk predictors from history, physical examination, and laboratory studies associated with adverse outcomes from selected studies.

Table 5  Examples of Syncope Risk Scores

<table>
<thead>
<tr>
<th>Study/Reference</th>
<th>Year</th>
<th>Sample N</th>
<th>Events N (%)</th>
<th>Outcome Definition</th>
<th>ED Events</th>
<th>Predictors</th>
<th>NPV (%)†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martin65</td>
<td>1997</td>
<td>252</td>
<td>104 (41%)</td>
<td>1-y death/arrhythmia</td>
<td>Yes</td>
<td>Abnormal ECG‡; &gt;45 y of age; VA; HF</td>
<td>93</td>
</tr>
<tr>
<td>Sarasin54</td>
<td>2003</td>
<td>175</td>
<td>30 (17%)</td>
<td>Inpatient arrhythmia</td>
<td>Yes</td>
<td>Abnormal ECG‡; &gt;65 y of age; HF</td>
<td>98</td>
</tr>
<tr>
<td>OESSIL47</td>
<td>2003</td>
<td>270</td>
<td>31 (11%)</td>
<td>1-y death</td>
<td>N/A</td>
<td>Abnormal ECG‡; &gt;65 y of age; no prodrome; cardiac history</td>
<td>100</td>
</tr>
<tr>
<td>SFSR52</td>
<td>2004</td>
<td>684</td>
<td>79 (12%)</td>
<td>7-d serious events‡</td>
<td>Yes</td>
<td>Abnormal ECG‡; dyspnea; hematoctrit; systolic BP &lt;90 mm Hg; HF</td>
<td>99</td>
</tr>
<tr>
<td>Boston Syncope Rule50</td>
<td>2007</td>
<td>293</td>
<td>68 (23%)</td>
<td>30-d serious events</td>
<td>Yes</td>
<td>Symptoms of acute coronary syndrome; worrisome cardiac history; family history of SCD; VHD; signs of conduction disease; volume depletion; persistent abnormal vital signs; primary central nervous event</td>
<td>100</td>
</tr>
<tr>
<td>Del Rosso49</td>
<td>2008</td>
<td>260</td>
<td>44 (17%)</td>
<td>Cardiac etiology</td>
<td>N/A</td>
<td>Abnormal ECG‡; cardiac history; palpitations; exertional; supine; precipitant (a low-risk factor); autonomic prodrome (low-risk factors)</td>
<td>99</td>
</tr>
<tr>
<td>STePS48</td>
<td>2008</td>
<td>676</td>
<td>41 (6%)</td>
<td>10-d serious events¶</td>
<td>Yes</td>
<td>Abnormal ECG‡; trauma; no prodrome; — male sex</td>
<td>—</td>
</tr>
<tr>
<td>Syncope Risk Score55</td>
<td>2009</td>
<td>2,584</td>
<td>173 (7%)</td>
<td>30-d serious events#</td>
<td>No</td>
<td>Abnormal ECG‡; &gt;90 y of age; male sex; positive troponin; history of arrhythmia; systolic BP &gt;160 mm Hg; near-syncope (a low-risk factor)</td>
<td>97</td>
</tr>
<tr>
<td>ROSE53</td>
<td>2010</td>
<td>550</td>
<td>40 (7%)</td>
<td>30-d serious events#</td>
<td>Yes</td>
<td>Abnormal ECG‡; B-natriuretic peptide; hemoglobin; O2Sat; fecal occult blood</td>
<td>98</td>
</tr>
</tbody>
</table>

AVB indicates atrioventricular block; BBB, bundle-branch block; BP, blood pressure; ECG, electrocardiogram; ED, emergency department; HF, heart failure; MI, myocardial infarction; N/A, not available; NPV, negative predictive value; O2Sat, oxygen saturation; OESSIL, Osservatorio Epidemiologico sulla Sincope nel Lazio; ROSE, Risk Stratification of Syncope in the ED; SCD, sudden cardiac death; SFSR, San Francisco Syncope Rule; STePS, Short-Term Prognosis of Syncope Study; TIA, transient ischemic attack; VA, ventricular arrhythmias; and VHD, valvular heart disease.

*Did the study include events diagnosed during the ED evaluation?
†NPV: Negative predictive value for lowest-risk group for the specific events defined by the study.
‡Abnormal ECG is defined variably in these studies. In the context of syncope evaluation, an abnormal ECG is any rhythm other than normal sinus rhythm, conduction delays (BBB, type-2 second-degree AVB or third-degree AVB), presence of Q waves, ST abnormalities, or prolonged QT interval.
¶Events: death, MI, arrhythmia, pulmonary embolism, stroke, hemorrhage, or readmission.
#Events: death, major therapeutic procedure, MI, arrhythmia, pulmonary embolism, stroke, sepsis, hemorrhage, or life-threatening sequelae of syncope.
#Events: death, major therapeutic procedure, or readmission.
|8Events: death, arrhythmia, MI, new diagnosis of severe structural heart disease, pulmonary embolism, aortic dissection, stroke/TIA, cerebral hemorrhage, or significant anemia requiring blood transfusion.
2.3.4. Disposition After Initial Evaluation: Recommendations

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>B-NR</td>
<td>Hospital evaluation and treatment are recommended for patients presenting with syncope who have a serious medical condition potentially relevant to the cause of syncope identified during initial evaluation.</td>
</tr>
<tr>
<td>IIa</td>
<td>C-LD</td>
<td>It is reasonable to manage patients with presumptive reflex-mediated syncope in the outpatient setting in the absence of serious medical conditions.</td>
</tr>
<tr>
<td>IIa</td>
<td>B-R</td>
<td>In intermediate-risk patients with an unclear cause of syncope, use of a structured emergency department observation protocol can be effective in reducing hospital admission.</td>
</tr>
<tr>
<td>IIb</td>
<td>C-LD</td>
<td>It may be reasonable to manage selected patients with suspected cardiac syncope in the outpatient setting in the absence of serious medical conditions.</td>
</tr>
</tbody>
</table>

Figure 2  Patient Disposition After Initial Evaluation for Syncope.
Colors correspond to Class of Recommendation in Table 1.
ED indicates emergency department; and pts, patients.

Table 6  Examples of Serious Medical Conditions That Might Warrant Consideration of Further Evaluation and Therapy in a Hospital Setting

<table>
<thead>
<tr>
<th>Cardiac Arrhythmic Conditions</th>
<th>Cardiac or Vascular Nonarrhythmic Conditions</th>
<th>Noncardiac Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sustained or symptomatic VT</td>
<td>Cardiac ischemia</td>
<td>Severe anemia/gastrointestinal bleeding</td>
</tr>
<tr>
<td>Symptomatic conduction system disease or Mobitz II or third-degree heart block</td>
<td>Severe aortic stenosis</td>
<td>Major traumatic injury due to syncope</td>
</tr>
<tr>
<td>Symptomatic bradycardia or sinus pauses not related to neurally mediated syncope</td>
<td>Cardiac tamponade</td>
<td>Persistent vital sign abnormalities</td>
</tr>
<tr>
<td>Symptomatic SVT</td>
<td>HCM</td>
<td></td>
</tr>
<tr>
<td>Pacemaker/ICD malfunction</td>
<td>Severe prosthetic valve dysfunction</td>
<td></td>
</tr>
<tr>
<td>Inheritable cardiovascular conditions predisposing to arrhythmias</td>
<td>Pulmonary embolism</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aortic dissection</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acute HF</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderate-to-severe LV dysfunction</td>
<td></td>
</tr>
</tbody>
</table>

HCM indicates hypertrophic cardiomyopathy; HF, heart failure; ICD, implantable cardioverter-defibrillator; LV, left ventricular; SVT, supraventricular tachycardia; and VT, ventricular tachycardia.
3. Additional Evaluation and Diagnosis

See Figure 3 for additional evaluation and diagnosis for syncope and Table 7 for a summary of types of ambulatory cardiac rhythm monitoring devices. See Online Data Supplements 7 through 16 for data supporting Section 3.

### 3.1. Blood Testing: Recommendations

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
</table>
| IIa      | B-NR  | Targeted blood tests are reasonable in the evaluation of selected patients with syncope identified on the basis of clinical assessment from history, physical examination, and ECG.  
82                                                            |
| IIb      | C-LD  | Usefulness of brain natriuretic peptide and high-sensitivity troponin measurement is uncertain in patients for whom a cardiac cause of syncope is suspected.  
83-86                                                   |
| III: No Benefit | B-NR  | Routine and comprehensive laboratory testing is not useful in the evaluation of patients with syncope.  
87,88                                                  |

### 3.2. Cardiovascular Testing: Recommendations

#### 3.2.1. Cardiac Imaging: Recommendations

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
</table>
| IIa      | B-NR  | Transthoracic echocardiography can be useful in selected patients presenting with syncope if structural heart disease is suspected.  
82,84,86 | |
| IIb      | B-NR  | Computed tomography or magnetic resonance imaging may be useful in selected patients presenting with syncope of suspected cardiac etiology.  
91                                                            |
| III: No Benefit | B-NR  | Routine cardiac imaging is not useful in the evaluation of patients with syncope unless cardiac etiology is suspected on the basis of an initial evaluation, including history, physical examination, or ECG.  
89,92                                                  |
3.2.2. Stress Testing: Recommendation

**Recommendation for Stress Testing**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIa</td>
<td>C-LD</td>
<td>Exercise stress testing can be useful to establish the cause of syncope in selected patients who experience syncope or presyncope during exertion.(^{93,94})</td>
</tr>
</tbody>
</table>

3.2.3. Cardiac Monitoring: Recommendations

**Recommendations for Cardiac Monitoring**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C-EO</td>
<td>The choice of a specific cardiac monitor should be determined on the basis of the frequency and nature of syncope events.</td>
</tr>
</tbody>
</table>
| IIa | B-NR    | To evaluate selected ambulatory patients with syncope of suspected arrhythmic etiology, the following external cardiac monitoring approaches can be useful:  
1. Holter monitor\(^{97-99}\)  
2. Transtelephonic monitor\(^{96,100,101}\)  
3. External loop recorder\(^{96,100-102}\)  
4. Patch recorder\(^{103-105}\)  
5. Mobile cardiac outpatient telemetry.\(^{106,107}\) |
| IIa | B-R     | To evaluate selected ambulatory patients with syncope of suspected arrhythmic etiology, an implantable cardiac monitor can be useful.\(^{95,96,99,107-121}\) |

**Table 7  Cardiac Rhythm Monitors**

<table>
<thead>
<tr>
<th>Types of Monitor</th>
<th>Device Description</th>
<th>Patient Selection</th>
</tr>
</thead>
</table>
| Holter monitor\(^{97-99}\) | - A portable, battery-operated device  
- Continuous recording for 24–72 h; up to 2 wk with newer models  
- Symptom rhythm correlation can be achieved through a patient event diary and patient-activated annotations | - Symptoms frequent enough to be detected within a short period (24–72 h) of monitoring\(^{97-99}\) |
| Patient activated, transtelephonic monitor (event monitor)\(^{96,100,101}\) | - A recording device that transmits patient-activated data (live or stored) via an analog phone line to a central remote monitoring station (e.g., physician office) | - Frequent, spontaneous symptoms likely to recur within 2–6 wk  
- Limited use in patients with frank syncope associated with sudden incapacitation |
| External loop recorder (patient or auto triggered)\(^{96,100,101}\) | - A device that continuously records and stores rhythm data over weeks to months  
- Patient activated, or auto triggered (e.g., to record asymptomatic arrhythmias) to provide a recording of events antecedent to (3–14 min), during, and after (1–4 min) the triggered event  
- Newer models are equipped with a cellular phone, which transmits triggered data automatically over a wireless network to a remote monitoring system | - Frequent, spontaneous symptoms related to syncope, likely to recur within 2–6 wk |
| External patch recorders\(^{103-105}\) | - Patch device that continuously records and stores rhythm data, with patient-trigger capability to allow for symptom-rhythm correlation  
- No leads or wires, and adhesive to chest wall/sternum  
- Various models record from 2–14 d  
- Offers accurate means of assessing burden of atrial fibrillation  
- Patient activated, or auto triggered (e.g., to record asymptomatic arrhythmias) to provide a recording of events antecedent to, during, and after the triggered event | - Can be considered as an alternative to external loop recorder  
- Given that it is leadless, can be accurately self-applied, and is largely water resistant, it may be more comfortable and less cumbersome than an external loop recorder, potentially improving compliance  
- Unlike Holter monitors and other external monitors, it offers only 1-lead recording |

(Continued)
3.2.4. In-Hospital Telemetry: Recommendation

**Recommendation for In-Hospital Telemetry**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>B-NR</td>
<td>Continuous ECG monitoring is useful for hospitalized patients admitted for syncope evaluation with suspected cardiac etiology. ²,125,126</td>
</tr>
</tbody>
</table>

3.2.5. Electrophysiological Study: Recommendations

**Recommendations for Electrophysiological Study (EPS)**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIa</td>
<td>B-NR</td>
<td>EPS can be useful for evaluation of selected patients with syncope of suspected arrhythmic etiology. ⁹⁷,₁₂⁷-₁₃⁴</td>
</tr>
<tr>
<td>III: No Benefit</td>
<td>B-NR</td>
<td>EPS is not recommended for syncope evaluation in patients with a normal ECG and normal cardiac structure and function, unless an arrhythmic etiology is suspected. ¹³⁴-₁₃⁶</td>
</tr>
</tbody>
</table>

3.2.6. Tilt-Table Testing: Recommendations

**Recommendations for Tilt-Table Testing**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIa</td>
<td>B-R</td>
<td>If the diagnosis is unclear after initial evaluation, tilt-table testing can be useful for patients with suspected vasovagal syncope (VVS). ¹³⁷-₁₄²</td>
</tr>
<tr>
<td>IIa</td>
<td>B-NR</td>
<td>Tilt-table testing can be useful for patients with syncope and suspected delayed OH when initial evaluation is not diagnostic. ¹⁴³,¹⁴⁴</td>
</tr>
<tr>
<td>IIa</td>
<td>B-NR</td>
<td>Tilt-table testing is reasonable to distinguish convulsive syncope from epilepsy in selected patients. ¹⁴⁵-¹⁴⁸</td>
</tr>
<tr>
<td>IIa</td>
<td>B-NR</td>
<td>Tilt-table testing is reasonable to establish a diagnosis of pseudosyncope. ¹⁴⁹-¹⁵¹</td>
</tr>
<tr>
<td>III: No Benefit</td>
<td>B-R</td>
<td>Tilt-table testing is not recommended to predict a response to medical treatments for VVS. ¹⁵²,¹⁵³</td>
</tr>
</tbody>
</table>
3.3. Neurological Testing: Recommendations

3.3.1. Autonomic Evaluation: Recommendation

**Recommendation for Autonomic Evaluation**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIa</td>
<td>C-LD</td>
<td>Referral for autonomic evaluation can be useful to improve diagnostic and prognostic accuracy in selected patients with syncope and known or suspected neurodegenerative disease.</td>
</tr>
</tbody>
</table>

3.3.2. Neurological and Imaging Diagnostics: Recommendations

**Recommendations for Neurological Diagnostics**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIa</td>
<td>C-LD</td>
<td>Simultaneous monitoring of an electroencephalogram and hemodynamic parameters during tilt-table testing can be useful to distinguish among syncope, pseudosyncope, and epilepsy.</td>
</tr>
<tr>
<td>III: No Benefit</td>
<td>B-NR</td>
<td>Magnetic resonance imaging and computed tomography of the head are not recommended in the routine evaluation of patients with syncope in the absence of focal neurological findings or head injury that support further evaluation.</td>
</tr>
<tr>
<td>III: No Benefit</td>
<td>B-NR</td>
<td>Carotid artery imaging is not recommended in the routine evaluation of patients with syncope in the absence of focal neurological findings that support further evaluation.</td>
</tr>
<tr>
<td>III: No Benefit</td>
<td>B-NR</td>
<td>Routine recording of an electroencephalogram is not recommended in the evaluation of patients with syncope in the absence of specific neurological features suggestive of a seizure.</td>
</tr>
</tbody>
</table>

4. Management of Cardiovascular Conditions

See Online Data Supplements 17 through 24 for data supporting Section 4.

4.1. Arrhythmic Conditions: Recommendations

4.1.1. Bradycardia: Recommendation

**Recommendation for Bradycardia**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C-E0</td>
<td>In patients with syncope associated with bradycardia, GDMT is recommended.</td>
</tr>
</tbody>
</table>

4.1.2. Supraventricular Tachycardia: Recommendations

**Recommendations for Supraventricular Tachycardia**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C-E0</td>
<td>In patients with syncope and supraventricular tachycardia, GDMT is recommended.</td>
</tr>
<tr>
<td>I</td>
<td>C-E0</td>
<td>In patients with atrial fibrillation, GDMT is recommended.</td>
</tr>
</tbody>
</table>

4.1.3. Ventricular Arrhythmia: Recommendation

**Recommendation for Ventricular Arrhythmia (VA)**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C-E0</td>
<td>In patients with syncope and VA, GDMT is recommended.</td>
</tr>
</tbody>
</table>

4.2. Structural Conditions: Recommendations

4.2.1. Ischemic and Nonischemic Cardiomyopathy: Recommendation

**Recommendation for Ischemic and Nonischemic Cardiomyopathy**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C-E0</td>
<td>In patients with syncope associated with ischemic and nonischemic cardiomyopathy, GDMT is recommended.</td>
</tr>
</tbody>
</table>

4.2.2. Valvular Heart Disease: Recommendation

**Recommendation for Valvular Heart Disease**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C-E0</td>
<td>In patients with syncope associated with valvular heart disease, GDMT is recommended.</td>
</tr>
</tbody>
</table>

4.2.3. Hypertrophic Cardiomyopathy: Recommendation

**Recommendation for Hypertrophic Cardiomyopathy (HCM)**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C-E0</td>
<td>In patients with syncope associated with HCM, GDMT is recommended.</td>
</tr>
</tbody>
</table>
4.2.4. Arrhythmogenic Right Ventricular Cardiomyopathy: Recommendations

Recommendations for Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>B-NR</td>
<td>Implantable cardioverter-defibrillator (ICD) implantation is recommended in patients with ARVC who present with syncope and have a documented sustained VA.¹⁷⁷-¹⁸¹</td>
</tr>
<tr>
<td>IIa</td>
<td>B-NR</td>
<td>ICD implantation is reasonable in patients with ARVC who present with syncope of suspected arrhythmic etiology.¹⁷⁷-¹⁸²</td>
</tr>
</tbody>
</table>

4.2.5. Cardiac Sarcoidosis: Recommendations

Recommendations for Cardiac Sarcoidosis

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>B-NR</td>
<td>ICD implantation is recommended in patients with cardiac sarcoidosis presenting with syncope and documented spontaneous sustained VA.¹⁶⁹,¹⁸³-¹⁸⁵</td>
</tr>
<tr>
<td>I</td>
<td>C-EO</td>
<td>GDMT is recommended for patients with cardiac sarcoidosis presenting with syncope and conduction abnormalities.¹⁶⁹,¹⁸⁹-¹⁹²</td>
</tr>
<tr>
<td>IIa</td>
<td>B-NR</td>
<td>ICD implantation is reasonable in patients with cardiac sarcoidosis and syncope of suspected arrhythmic origin, particularly with left ventricular dysfunction or pacing indication.¹⁹³-¹⁹⁶</td>
</tr>
<tr>
<td>IIa</td>
<td>B-NR</td>
<td>EPS is reasonable in patients with cardiac sarcoidosis and syncope of suspected arrhythmic etiology.¹⁹⁷</td>
</tr>
</tbody>
</table>

4.3. Inheritable Arrhythmic Conditions: Recommendations

4.3.1. Brugada Syndrome: Recommendations

Recommendations for Brugada ECG Pattern and Syncope

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C-LD</td>
<td>Exercise restriction is recommended in patients with CPVT presenting with syncope of suspected arrhythmic etiology.²¹⁸-²²⁰</td>
</tr>
<tr>
<td>I</td>
<td>C-LD</td>
<td>Beta blockers lacking intrinsic sympathomimetic activity are recommended in patients with CPVT and stress-induced syncope.²¹⁸,²²¹-²²⁵</td>
</tr>
<tr>
<td>IIa</td>
<td>C-LD</td>
<td>Flecainide is reasonable in patients with CPVT who continue to have syncope of suspected VA despite beta-blocker therapy.²¹²,²²⁶</td>
</tr>
<tr>
<td>IIa</td>
<td>B-NR</td>
<td>ICD therapy is reasonable in patients with CPVT and a history of exercise- or stress-induced syncope despite use of optimal medical therapy or left cardiac sympathetic denervation.¹⁹⁷,²²⁷,²²⁸</td>
</tr>
<tr>
<td>IIb</td>
<td>C-LD</td>
<td>In patients with CPVT who continue to experience syncope or VA, verapamil with or without beta-blocker therapy may be considered.¹²⁹,²³⁰</td>
</tr>
<tr>
<td>IIb</td>
<td>C-LD</td>
<td>Left cardiac sympathetic denervation may be reasonable in patients with CPVT, syncope, and symptomatic VA despite optimal medical therapy.²³¹-²³³</td>
</tr>
</tbody>
</table>

4.3.2. Short-QT Syndrome: Recommendation

Recommendation for Short-QT Syndrome

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIB</td>
<td>C-EO</td>
<td>ICD implantation may be considered in patients with short-QT pattern and syncope of suspected arrhythmic etiology.</td>
</tr>
</tbody>
</table>

4.3.3. Long-QT Syndrome: Recommendations

Recommendations for Long-QT Syndrome (LQTS)

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>B-NR</td>
<td>Beta-blocker therapy, in the absence of contraindications, is indicated as a first-line therapy in patients with LQTS and suspected arrhythmic syncope.²⁰⁷-²⁰⁹</td>
</tr>
<tr>
<td>IIa</td>
<td>B-NR</td>
<td>ICD implantation is reasonable in patients with LQTS and suspected arrhythmic syncope who are on beta-blocker therapy or are intolerant to beta-blocker therapy.²⁰⁸,²¹⁰-²¹⁴</td>
</tr>
<tr>
<td>IIa</td>
<td>C-LD</td>
<td>Left cardiac sympathetic denervation is reasonable in patients with LQTS and recurrent syncope of suspected arrhythmic mechanism who are intolerant to beta-blocker therapy or for whom beta-blocker therapy has failed.²¹⁵-²¹⁷</td>
</tr>
</tbody>
</table>

4.3.4. Catecholaminergic Polymorphic Ventricular Tachycardia: Recommendations

Recommendations for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C-LD</td>
<td>Exercise restriction is recommended in patients with CPVT presenting with syncope of suspected arrhythmic etiology.²¹⁸-²²⁰</td>
</tr>
<tr>
<td>I</td>
<td>C-LD</td>
<td>Beta blockers lacking intrinsic sympathomimetic activity are recommended in patients with CPVT and stress-induced syncope.²¹⁸,²²¹-²²⁵</td>
</tr>
<tr>
<td>IIa</td>
<td>C-LD</td>
<td>Flecainide is reasonable in patients with CPVT who continue to have syncope of suspected VA despite beta-blocker therapy.²¹²,²²⁶</td>
</tr>
<tr>
<td>IIa</td>
<td>B-NR</td>
<td>ICD therapy is reasonable in patients with CPVT and a history of exercise- or stress-induced syncope despite use of optimal medical therapy or left cardiac sympathetic denervation.¹⁹⁷,²²⁷,²²⁸</td>
</tr>
<tr>
<td>IIb</td>
<td>C-LD</td>
<td>In patients with CPVT who continue to experience syncope or VA, verapamil with or without beta-blocker therapy may be considered.¹²⁹,²³⁰</td>
</tr>
<tr>
<td>IIb</td>
<td>C-LD</td>
<td>Left cardiac sympathetic denervation may be reasonable in patients with CPVT, syncope, and symptomatic VA despite optimal medical therapy.²³¹-²³³</td>
</tr>
</tbody>
</table>
4.3.5. **Early Repolarization Pattern: Recommendations**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIb</td>
<td>C-EO</td>
<td>ICD implantation may be considered in patients with early repolarization pattern and suspected arrhythmic syncope in the presence of a family history of early repolarization pattern with cardiac arrest.</td>
</tr>
<tr>
<td>III: Harm</td>
<td>B-NR</td>
<td>EPS should not be performed in patients with early repolarization pattern and history of syncope in the absence of other indications.</td>
</tr>
</tbody>
</table>

5. **Reflex Conditions: Recommendations**

See Figure 4 for the algorithm for treatment of VVS. See Online Data Supplements 25 through 32 for data supporting Section 5.

5.1. **Vasovagal Syncope: Recommendations**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C-EO</td>
<td>Patient education on the diagnosis and prognosis of VVS is recommended.</td>
</tr>
<tr>
<td>IIa</td>
<td>B-R</td>
<td>Physical counter-pressure maneuvers can be useful in patients with VVS who have a sufficiently long prodromal period.</td>
</tr>
<tr>
<td>IIa</td>
<td>B-R</td>
<td>Midodrine is reasonable in patients with recurrent VVS with no history of hypertension, heart failure, or urinary retention.</td>
</tr>
<tr>
<td>IIb</td>
<td>B-R</td>
<td>The usefulness of orthostatic training is uncertain in patients with frequent VVS.</td>
</tr>
<tr>
<td>IIb</td>
<td>B-R</td>
<td>Fludrocortisone might be reasonable for patients with recurrent VVS and inadequate response to salt and fluid intake, unless contraindicated.</td>
</tr>
<tr>
<td>IIb</td>
<td>B-NR</td>
<td>Beta blockers might be reasonable in patients 42 years of age or older with recurrent VVS.</td>
</tr>
<tr>
<td>IIb</td>
<td>C-LD</td>
<td>Encouraging increased salt and fluid intake may be reasonable in selected patients with VVS, unless contraindicated.</td>
</tr>
<tr>
<td>IIb</td>
<td>C-LD</td>
<td>In selected patients with VVS, it may be reasonable to reduce or withdraw medications that cause hypotension when appropriate.</td>
</tr>
<tr>
<td>IIb</td>
<td>C-LD</td>
<td>In patients with recurrent VVS, a selective serotonin reuptake inhibitor might be considered.</td>
</tr>
</tbody>
</table>

**Figure 4** Vasovagal Syncope.
Colors correspond to Class of Recommendation in Table 1.
VVS indicates vasovagal syncope.
5.2. Pacemakers in Vasovagal Syncope: Recommendation
See the ERC systematic review report “Pacing as a Treatment for Reflex-Mediated (Vasovagal, Situational, or Carotid Sinus Hypersensitivity) Syncope” for the complete systematic evidence review. Recommendations that are based on a body of evidence that includes the systematic review conducted by the ERC are denoted by the superscript SR (e.g., LOE B-R SR).

<table>
<thead>
<tr>
<th>Recommendation for Pacemakers in VVS</th>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIb B-R SR</td>
<td></td>
<td></td>
<td>Dual-chamber pacing might be reasonable in a select population of patients 40 years of age or older with recurrent VVS and prolonged spontaneous pauses.</td>
</tr>
</tbody>
</table>

SR indicates systematic review.

5.3. Carotid Sinus Syndrome: Recommendations

Recommendations for Carotid Sinus Syndrome

<table>
<thead>
<tr>
<th>Recommendations for Carotid Sinus Syndrome</th>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIa B-R</td>
<td></td>
<td></td>
<td>Permanent cardiac pacing is reasonable in patients with carotid sinus syndrome that is cardioinhibitory or mixed.</td>
</tr>
<tr>
<td>IIb B-R</td>
<td></td>
<td></td>
<td>It may be reasonable to implant a dual-chamber pacemaker in patients with carotid sinus syndrome who require permanent pacing.</td>
</tr>
</tbody>
</table>

5.4. Other Reflex Conditions
Situational syncope is defined as syncope occurring only in certain distinct and usually memorable circumstances, including micturition syncope, defecation syncope, cough syncope, laugh syncope, and swallow syncope. Appropriate investigations should be undertaken to determine an underlying etiology, including causes that may be reversible. Evidence for treatment is limited mainly to case reports, small case series, and small observational studies. Treatment of most types of situational syncope relies heavily on avoidance or elimination of a triggering event. This may not always be possible, so increased fluid and salt consumption and reduction or removal of hypotensive drugs and diuretics are encouraged where appropriate and safe.

6. Orthostatic Hypotension: Recommendations
See Figure 5 for the algorithm for treating orthostatic hypotension (OH). See Online Data Supplements 33 through 37 for data supporting Section 6.

Recommendations for Neurogenic Orthostatic Hypotension (OH)

<table>
<thead>
<tr>
<th>Recommendations for Neurogenic Orthostatic Hypotension (OH)</th>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIa B-R</td>
<td></td>
<td></td>
<td>Acute water ingestion is recommended in patients with syncope caused by neurogenic OH for occasional, temporary relief.</td>
</tr>
<tr>
<td>IIa C-LD</td>
<td></td>
<td></td>
<td>Physical counter-pressure maneuvers can be beneficial in patients with neurogenic OH with syncope.</td>
</tr>
<tr>
<td>IIa</td>
<td></td>
<td></td>
<td>Compression garments can be beneficial in patients with syncope and OH.</td>
</tr>
<tr>
<td>IIa B-R</td>
<td></td>
<td></td>
<td>Midodrine can be beneficial in patients with syncope due to neurogenic OH.</td>
</tr>
<tr>
<td>IIa B-R</td>
<td></td>
<td></td>
<td>Droxidopa can be beneficial in patients with syncope due to neurogenic OH.</td>
</tr>
<tr>
<td>IIa C-LD</td>
<td></td>
<td></td>
<td>Fludrocortisone can be beneficial in patients with syncope due to neurogenic OH.</td>
</tr>
<tr>
<td>IIb C-LD</td>
<td></td>
<td></td>
<td>Encouraging increased salt and fluid intake may be reasonable in selected patients with neurogenic OH.</td>
</tr>
<tr>
<td>IIb C-LD</td>
<td></td>
<td></td>
<td>Pyridostigmine may be beneficial in patients with syncope due to neurogenic OH who are refractory to other treatments.</td>
</tr>
<tr>
<td>IIb C-LD</td>
<td></td>
<td></td>
<td>Octreotide may be beneficial in patients with syncope and refractory recurrent postprandial or neurogenic OH.</td>
</tr>
</tbody>
</table>
6.2. Dehydration and Drugs: Recommendations

**Recommendations for Dehydration and Drugs**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C-LD</td>
<td>Fluid resuscitation via oral or intravenous bolus is recommended in patients with syncope due to acute dehydration.(^{287,327-331})</td>
</tr>
<tr>
<td>IIA</td>
<td>B-NR</td>
<td>Reducing or withdrawing medications that may cause hypotension can be beneficial in selected patients with syncope.(^{332-339})</td>
</tr>
<tr>
<td>IIA</td>
<td>C-LD</td>
<td>In selected patients with syncope due to dehydration, it is reasonable to encourage increased salt and fluid intake.(^{344,328,330,331,340,341})</td>
</tr>
</tbody>
</table>

7. Orthostatic Intolerance

Orthostatic intolerance is a general term referring to frequent, recurrent, or persistent symptoms that develop upon standing (usually with a change in position from sitting or lying to an upright position) and are relieved by sitting or lying.\(^{8}\) Most commonly, the symptoms include lightheadedness, palpitations, tremulousness, generalized weakness, blurred vision, exercise intolerance, and fatigue. These symptoms may be accompanied by hemodynamic disturbances, including blood pressure decrease, which may or may not meet criteria for OH, and heart rate increase, which may be inadequate or compensatory.\(^{8}\) The pathophysiology is quite varied. One condition of note is Postural Tachycardia Syndrome (POTS), in which upright posture results in an apparently inappropriate tachycardia, usually with heart rates >120 bpm.\(^{9}\)

Although syncope occurs in patients with POTS, it is relatively infrequent, and there is little evidence that the syncope is due to POTS.\(^{9,10}\) Treatments that improve symptoms of POTS might decrease the occurrence of syncope, although this is unknown.\(^{9-19}\) For further guidance on the management of POTS, we refer readers to the Heart Rhythm Society consensus statement.\(^{9}\)
8. Pseudosyncope: Recommendations
See Online Data Supplements 38 and 39 for data supporting Section 8.

### Recommendations for the Treatment of Pseudosyncope

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIb</td>
<td>C-LD</td>
<td>In patients with suspected pseudosyncope, a candid discussion with the patient about the diagnosis may be reasonable. Cognitive behavioral therapy may be beneficial in patients with pseudosyncope.</td>
</tr>
</tbody>
</table>

9. Uncommon Conditions Associated With Syncope
Table 9 in the full-text guideline provides a list of less common conditions associated with syncope.

10. Age, Lifestyle, and Special Populations: Recommendations
See Online Data Supplements 40 to 42 for data supporting Section 10.

10.1. Pediatric Syncope: Recommendations

### Recommendations for Pediatric Syncope

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C-LD</td>
<td>VVS evaluation, including a detailed medical history, physical examination, family history, and a 12-lead ECG, should be performed in all pediatric patients presenting with syncope.</td>
</tr>
<tr>
<td>I</td>
<td>C-LD</td>
<td>Noninvasive diagnostic testing should be performed in pediatric patients presenting with syncope and suspected congenital heart disease, cardiomyopathy, or primary rhythm disorder.</td>
</tr>
<tr>
<td>I</td>
<td>C-EO</td>
<td>Education on symptom awareness of prodromes and reassurance are indicated in pediatric patients with VVS.</td>
</tr>
<tr>
<td>IIa</td>
<td>C-LD</td>
<td>Tilt-table testing can be useful for pediatric patients with suspected VVS when the diagnosis is unclear.</td>
</tr>
<tr>
<td>IIa</td>
<td>B-R</td>
<td>In pediatric patients with VVS not responding to lifestyle measures, it is reasonable to prescribe midodrine.</td>
</tr>
<tr>
<td>IIb</td>
<td>B-R</td>
<td>Encouraging increased salt and fluid intake may be reasonable in selected pediatric patients with VVS.</td>
</tr>
<tr>
<td>IIb</td>
<td>C-LD</td>
<td>The effectiveness of fludrocortisone is uncertain in pediatric patients with OH associated with syncope.</td>
</tr>
<tr>
<td>IIb</td>
<td>B-NR</td>
<td>Cardiac pacing may be considered in pediatric patients with severe neurally mediated syncope secondary to pallid breath-holding spells.</td>
</tr>
<tr>
<td>III: No Benefit</td>
<td>B-R</td>
<td>Beta blockers are not beneficial in pediatric patients with VVS.</td>
</tr>
</tbody>
</table>

10.2. Adult Congenital Heart Disease: Recommendations

### Recommendations for ACHD

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIa</td>
<td>C-EO</td>
<td>For evaluation of patients with ACHD and syncope, referral to a specialist with expertise in ACHD can be beneficial.</td>
</tr>
<tr>
<td>IIa</td>
<td>B-NR</td>
<td>EPS is reasonable in patients with moderate or severe ACHD and unexplained syncope.</td>
</tr>
</tbody>
</table>

10.3. Geriatric Patients: Recommendations

### Recommendations for Geriatric Patients

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIa</td>
<td>C-EO</td>
<td>For the assessment and management of older adults with syncope, a comprehensive approach in collaboration with an expert in geriatric care can be beneficial.</td>
</tr>
<tr>
<td>IIa</td>
<td>B-NR</td>
<td>It is reasonable to consider syncope as a cause of nonaccidental falls in older adults.</td>
</tr>
</tbody>
</table>
10.4. Driving and Syncope: Recommendation

The suggestions in Table 8 provide general guidance for private drivers. Most suggestions are based on expert opinion and supported by limited data. Commercial driving in the United States is governed by federal law and administered by the U.S. Department of Transportation.

**Recommendation for Driving and Syncope**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIa</td>
<td>C-E0</td>
<td>It can be beneficial for healthcare providers managing patients with syncope to know the driving laws and restrictions in their regions and discuss implications with the patient.</td>
</tr>
</tbody>
</table>

**Table 8 Avoidance of Private Driving After an Episode of Syncope: Suggested Symptom-Free Waiting Times for Various Conditions**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Symptom-Free Waiting Time*</th>
</tr>
</thead>
<tbody>
<tr>
<td>OH, no syncope in prior year</td>
<td>1 month</td>
</tr>
<tr>
<td>VVS, 1–6 syncope per year</td>
<td>1 month</td>
</tr>
<tr>
<td>VVS, &gt;6 syncope per year</td>
<td>Not fit to drive until symptoms resolved</td>
</tr>
<tr>
<td>Situational syncope other than cough syncope</td>
<td>1 month</td>
</tr>
<tr>
<td>Cough syncope, untreated</td>
<td>Not fit to drive</td>
</tr>
<tr>
<td>Cough syncope, treated with cough suppression</td>
<td>1 month</td>
</tr>
<tr>
<td>Carotid sinus syncope, untreated</td>
<td>Not fit to drive</td>
</tr>
<tr>
<td>Carotid sinus syncope, treated with permanent pacemaker</td>
<td>1 week</td>
</tr>
<tr>
<td>Syncope due to nonreflex bradycardia, untreated</td>
<td>Not fit to drive</td>
</tr>
<tr>
<td>Syncope due to nonreflex bradycardia, treated with permanent pacemaker</td>
<td>1 week</td>
</tr>
<tr>
<td>Syncope due to SVT, untreated</td>
<td>Not fit to drive</td>
</tr>
<tr>
<td>Syncope due to SVT, pharmacologically suppressed</td>
<td>1 month</td>
</tr>
<tr>
<td>Syncope due to SVT, treated with ablation</td>
<td>1 week</td>
</tr>
<tr>
<td>Syncope with LVEF &lt;35% and a presumed arrhythmic etiology without an ICD</td>
<td>Not fit to drive</td>
</tr>
<tr>
<td>Syncope with LVEF &lt;35% and presumed arrhythmic etiology with an ICD</td>
<td>3 months</td>
</tr>
<tr>
<td>Syncope presumed due to VT/VF, structural heart disease and LVEF ≥35%, untreated</td>
<td>Not fit to drive</td>
</tr>
<tr>
<td>Syncope presumed due to VT/VF, structural heart disease and LVEF ≥35%, treated with an ICD and guideline-directed drug therapy</td>
<td>3 months</td>
</tr>
<tr>
<td>Syncope presumed due to VT with a genetic cause, untreated</td>
<td>Not fit to drive</td>
</tr>
<tr>
<td>Syncope presumed due to VT with a genetic cause, treated with an ICD or guideline-directed drug therapy</td>
<td>3 months</td>
</tr>
<tr>
<td>Syncope presumed due to a nonstructural heart disease VT, such as RVOT or LVOT, untreated</td>
<td>Not fit to drive</td>
</tr>
<tr>
<td>Syncope presumed due to a nonstructural heart disease VT, such as RVOT or LVOT, treated successfully with ablation or suppressed pharmacologically</td>
<td>3 months</td>
</tr>
<tr>
<td>Syncope of undetermined etiology</td>
<td>1 month</td>
</tr>
</tbody>
</table>

ICD indicates implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract; OH, orthostatic hypotension; RVOT, right ventricular outflow tract; SVT, supraventricular tachycardia; VF, ventricular fibrillation; VT, ventricular tachycardia; and VVS, vasovagal syncope.

*It may be prudent to wait and observe for this time without a syncope spell before resuming driving.

10.5. Athletes: Recommendations

**Recommendations for Athletes**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C-E0</td>
<td>Cardiovascular assessment by a care provider experienced in treating athletes with syncope is recommended prior to resuming competitive sports.</td>
</tr>
<tr>
<td>IIa</td>
<td>C-LD</td>
<td>Assessment by a specialist with disease-specific expertise is reasonable for athletes with syncope and high-risk markers. 387,389</td>
</tr>
<tr>
<td>IIa</td>
<td>C-LD</td>
<td>Extended monitoring can be beneficial for athletes with unexplained exertional syncope after an initial cardiovascular evaluation. 390,391</td>
</tr>
<tr>
<td>III: Harm</td>
<td>B-NR</td>
<td>Participation in competitive sports is not recommended for athletes with syncope and phenotype-positive HCM, CPVT, LQTS1, or ARVC before evaluation by a specialist. 392-396</td>
</tr>
</tbody>
</table>
11. Quality of Life and Healthcare Cost of Syncope
11.1. Impact of Syncope on Quality of Life
QoL is reduced with recurrent syncope, as demonstrated in studies that compared patients with and without syncope. Similarly, pediatric patients with recurrent syncope reported worse QoL than individuals with diabetes mellitus and equivalent QoL to individuals with asthma, end-stage renal disease, and structural heart disease.

11.2. Healthcare Costs Associated With Syncope
High healthcare costs are associated with the evaluation and management of syncope. These high costs have been estimated both in the United States and abroad.

12. Emerging Technology, Evidence Gaps, and Future Directions
The writing committee created a list of key areas in which knowledge gaps are present in the evaluation and management of patients presenting with syncope. These knowledge gaps present opportunities for future research to ultimately improve clinical outcomes and effectiveness of healthcare delivery.

12.1. Definition, Classification, and Epidemiology
Reported incidence and prevalence of syncope vary significantly because of several confounders: variable definitions for syncope versus transient loss of consciousness, different populations, different clinical settings, and different study methodologies. Definition and classification of syncope provided in this document will set the standard for future research. Standardized national registries and large sample databases are needed to gather data on a continuous basis to understand the true incidence and prevalence of syncope, understand patient risk, inform driving policies, improve patient outcomes, and improve and streamline health service delivery.

12.2. Risk Stratification and Clinical Outcomes
- Studies are needed to determine whether syncope is an independent predictor of nonfatal or fatal outcomes in selected patient populations.
- Studies are needed to develop risk scores to be prospectively validated in a given clinical setting with predefined endpoints from short- and long-term follow-up.
- Prospective and well-designed studies are needed to define relevant clinical outcomes with regard to recurrent syncope, nonfatal outcomes such as injury, and fatal outcomes. Future studies should incorporate quality of life, work loss, and functional capacity as additional clinical endpoints.
- Prospective studies are needed to differentiate cardiac and noncardiac clinical outcomes in different clinical settings and with different follow-up durations.
- Among patients without identifiable causes of syncope, studies are needed to determine short- and long-term outcomes to guide the overall management of these patients.

12.3. Evaluation and Diagnosis
- Studies are needed to better understand the interaction and relationships among the presenting symptom of syncope, the cause of syncope, the underlying disease condition, and their effect on clinical outcomes.
- Investigations are needed to understand the key components of clinical characteristics during the initial evaluation and to develop standardization tools to guide the evaluation by healthcare team.
- RCTs are needed to develop structured protocols to evaluate patients with syncope who are at intermediate risk without an immediate presumptive diagnosis. In addition to the endpoints of diagnostic yield and healthcare utilization, relevant clinical endpoints of nonfatal and fatal outcomes and recurrence of syncope are to be included.
- RCTs are needed to determine the features of syncope-specialized facilities that are necessary to achieve beneficial outcomes for patient care and to improve efficiency and effectiveness of healthcare delivery.
- As technology advances, studies are needed to determine the value of new technology in the evaluation and management of patients with syncope.

12.4. Management of Specific Conditions
- Although potential causes of syncope are multiple, a treatment decision is usually fairly straightforward for patients with cardiac causes of syncope or orthostatic causes. VVS is the most common cause of syncope in the general population. Treatment remains challenging in patients who have recurrences despite conservative therapy. Studies are needed to differentiate “arrhythmic syncope” versus “non-arrhythmic syncope” versus “aborted SCD” in patients with inheritable arrhythmic conditions.
- Prospectively designed multicenter or national registries are needed to gather clinical information from patients with reflex syncope to better our understanding on other associated conditions, plausible mechanisms, effectiveness of therapeutic interventions, and natural history of these uncommon conditions.
- RCTs are needed to continue the identification of effective treatment approaches to patients with recurrent reflex syncope.

12.5. Special Populations
- Questions and research about risk stratification, evaluation, and management outlined above for the adult population are needed in the pediatric population, geriatric population, and athletes.
Prospective national registries and big databases are needed to determine risk associated with driving among different populations with syncope.

Prospective and randomized studies are needed to assess the usefulness of specialized syncope units in different clinical settings.

### Presidents and Staff

**American College of Cardiology**

Richard A. Chazal, MD, FACC, President
Shalom Jacobovitz, Chief Executive Officer
William J. Oetgen, MD, MBA, FACC, Executive Vice President, Science, Education, Quality, and Publishing
Amelia Scholtz, PhD, Publications Manager, Science, Education, Quality, and Publishing

**American College of Cardiology/American Heart Association**

Katherine Sheehan, PhD, Director, Guideline Methodology and Policy
Abdul R. Abdullah, MD, Science and Medicine Advisor
Clara Fitzgerald, Project Manager, Science and Clinical Policy
Allison Rabinowitz, MPH, Project Manager, Science and Clinical Policy

**American Heart Association**

Steven R. Houser, PhD, FAHA, President
Nancy Brown, Chief Executive Officer
Rose Marie Robertson, MD, FAHA, Chief Science and Medicine Officer
Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice President, Office of Science Operations
Jody Hundley, Production Manager, Scientific Publications, Office of Science Operations

### Appendix

**Supplementary data**

Writing Committee Comprehensive Relationship With Industry table and Data Supplement associated with this article can be found at [http://dx.doi.org/10.1016/j.hrthm.2017.03.005](http://dx.doi.org/10.1016/j.hrthm.2017.03.005).

### References


### Appendix 1  Author Relationships With Industry and Other Entities (Relevant)—2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope (March 2015)

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
<th>Voting Recusals by Section*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Win-Kuang Shen (Chair)</td>
<td>Mayo Clinic Arizona—Professor of Medicine; Mayo Clinic College of Medicine—Chair, Department of Cardiovascular Diseases</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Robert S. Sheldon (Vice Chair)</td>
<td>University of Calgary, Department of Medicine—Professor</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>David G. Benditt</td>
<td>University of Minnesota Medical School, Cardiovascular Division—Professor of Medicine</td>
<td>Medtronic†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>3.2, 3.2.3, 3.2.5, 4.1.1–4.1.3, 4.2.1–4.2.5, 4.3.1–4.3.5, 5.1–5.3, 10.1, 10.2, 10.3, 10.5, 12</td>
</tr>
<tr>
<td>Mitchell I. Cohen</td>
<td>University of Arizona School of Medicine-Phoenix—Clinical Professor of Child Health; Phoenix Children’s Heart Center—Co-Director; Phoenix Children’s Hospital, Pediatric Cardiology—Chief</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>3.2, 3.2.3, 3.2.5, 4.1.1–4.1.3, 4.2.1–4.2.5, 4.3.1–4.3.5, 5.1–5.3, 10.1, 10.2, 10.3, 10.5, 12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Daniel E. Forman</td>
<td>University of Pittsburgh—Professor of Medicine; University of Pittsburgh Medical Center—Chair, Geriatric Cardiology Section; VA Pittsburgh Healthcare Systems—Director, Cardiac Rehabilitation</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Roy Freeman†</td>
<td>Harvard Medical School—Professor of Neurology; Beth Israel Deaconess Medical Center, Center for Autonomic and Peripheral Nerve Disorders—Director</td>
<td>Lundbeck†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>4.3.1–4.3.5, 5.1, 6.1, 10.1, 10.3, 10.5, 12</td>
</tr>
<tr>
<td>Zachary D. Goldberger</td>
<td>University of Washington School of Medicine, Harborview Medical Center Division of Cardiology—Assistant Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Blair P. Grubb</td>
<td>University of Toledo Medical Center, Medicine and Pediatrics—Professor</td>
<td>Biotronik</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>3.2, 3.2.3, 3.2.5, 4.1.1–4.1.3, 4.2.1–4.2.5, 4.3.1–4.3.5, 5.1–5.3, 10.1, 10.2, 10.3, 10.5, 12</td>
</tr>
<tr>
<td>Mohamed H. Hamdan</td>
<td>University of Wisconsin School of Medicine, Cardiovascular Medicine—Professor and Chief of Cardiovascular Medicine</td>
<td>None</td>
<td>F2 Solutions</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>2.3.3, 2.3.4, 12</td>
</tr>
<tr>
<td>Andrew D. Krahn</td>
<td>The University of British Columbia, Division of Cardiology—Professor of Medicine and Head of Division</td>
<td>Medtronic†</td>
<td>None</td>
<td>None</td>
<td>Boston Scientific†</td>
<td>Medtronic†</td>
<td>None</td>
<td>3.2, 3.2.3, 3.2.5, 4.1.1–4.1.3, 4.2.1–4.2.5, 4.3.1–4.3.5, 5.1–5.3, 10.1, 10.2, 10.3, 10.5, 12</td>
</tr>
<tr>
<td>Mark S. Link</td>
<td>University of Texas Southwestern Medical Center, Department of Medicine, Division of Cardiology—Director, Cardiac Electrophysiology; Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

(Continued)
### Appendix 1 (Continued)

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
<th>Voting Recusals by Section*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Olshansky</td>
<td>University of Iowa Carver College of Medicine, Cardiovascular Medicine—Emeritus Professor of Internal Medicine; Mercy Hospital North Iowa—Electrophysiologist</td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Satish R. Raj</td>
<td>University of Calgary, Cardiac Sciences—Associate Professor</td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Medtronic</td>
<td>None</td>
<td>2.3.2, 2.3.4, 3.2–3.2.5, 3.3.2, 4.1.1–4.1.3, 4.2.1–4.2.5, 4.3.1–4.3.5, 5.1–5.3, 6.1, 7, 10.1–10.3, 10.5, 12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Roopinder Kaur Sandhu</td>
<td>University of Alberta, Medical Division of Cardiology—Assistant Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dan Sorajja</td>
<td>Mayo Clinic Arizona, Cardiovascular Diseases—Assistant Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Benjamin C. Sun</td>
<td>Oregon Health &amp; Science University—Associate Professor</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Clyde W. Yancy</td>
<td>Northwestern University Feinberg School of Medicine, Division of Cardiology—Professor of Medicine and Chief; Diversity &amp; Inclusion—Vice Dean</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply (section numbers correspond to the full-text guideline).

ACC = American College of Cardiology; AHA = American Heart Association; HRS = Heart Rhythm Society; VA = Veterans Affairs.

This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household, has a reasonable potential for financial, professional, or other personal gain or loss as a result of the issues/content addressed in the document.

Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply (section numbers correspond to the full-text guideline).

Significant relationship.

Dr. Roy Freeman, the official representative of the American Academy of Neurology, resigned from the writing committee in November 2016, before the final balloting process; recusals noted are from the initial round of balloting. We thank him for his contributions.
## Appendix 2  Reviewer Relationships With Industry and Other Entities (Comprehensive)—2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope (June 2016)

<table>
<thead>
<tr>
<th>Reviewer</th>
<th>Representation</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
</table>
| Italo Biaggioni            | Official Reviewer—AHA | Vanderbilt University School of Medicine—Professor of Medicine | ● Lundbeck*  
● Shire Pharmaceuticals*  
● Theravance* | None            | None                                          | ● Astellas Pharma (DSMB)  
● AstraZeneca*  
● Forest Pharmaceuticals*  
● Janssen Pharmaceuticals (DSMB)  
● Lundbeck*  
● Theravance* | None            | None                                          |None            |
| Joaquin E. Cigarroa        | Official Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines | Oregon Health & Science University—Clinical Professor of Medicine | None                                      | None            | None                                          | ● NIH†  
● AHA†  
● SCAI†  
● ASA†  
● Catheterization and Cardiovascular Intervention† | None            | None                                          |None            |
| Kenneth A. Ellenbogen      | Official Reviewer—ACC/AHA | VCU Medical Center—Director, Clinical EP Laboratory | ● AHA  
● Atricure*  
● Biosense Webster*  
● Biotronik*  
● Boston Science*  
● HRS*  
● Janssen Pharmaceuticals  
● Medtronic*  
● Pfizer*  
● Sentra Heart  
● St. Jude Medical* | None            | None                                          | ● Atricure*  
● Boston Science  
● Biosense Webster  
● Daiichi-Sankyo*  
● Medtronic (DSMB)  
● Medtronic  
● NIH  
● Sanofi-aventis | ● AHA  
● American Heart Journal  
● Biosense Webster*  
● Boston Science*  
● HRS  
● JCE  
● Medtronic*  
● PACE  
● Sanofi-aventis | ● Defendant, Catheter ablation complication, 2015  
● Plantiff, Lead extraction complication, 2015 |
| Rakesh Gopinathannair      | Official Reviewer—HRS | University of Louisville School of Medicine and Jewish Hospital Division of Cardiovascular Medicine—Associate Professor of Medicine, Director of Cardiac EP | ● Boston Scientific Health Trust PG  
● St. Jude Medical*  
● AHA  
● Bristol-Myers Squibb  
● Pfizer*  
● Zoll Medical | None            | None                                          | None            | None                                          |None            |

(Continued)
<table>
<thead>
<tr>
<th>Reviewer</th>
<th>Representation</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
</table>
| Robert Helm              | Official Reviewer—HRS | Boston University School of Medicine—Assistant Professor of Medicine, Assistant Professor of Radiology | None       | None           | None                          | None             | ● Boston Scientific
● St. Jude Medical                                        |                |
| Dhanunjaya Lakkireddy    | Official Reviewer—ACC Board of Governors | University of Kansas Medical Center—Professor of Medicine; Center for Excellence in AF and Complex Arrhythmias—Director | ● Biosense Webster
● St. Jude Medical
● Boehringer Ingelheim
● Bristol-Myers Squibb
● Janssen Pharmaceuticals
● Pfizer           | None           | None                                                | None       | None           | None                          | None             | None                                                      |                |
| Thad Waites              | Official Reviewer—ACC Board of Trustees | Forrest General Hospital—Director of Catheterization Laboratory | None       | None           | None                          | None             | None                                                      |                |
| Christopher Gibbons      | Organizational Reviewer—AAN | Beth Israel Deaconess Medical Center Neuropathy Clinic—Director | ● Lundbeck  | None           | None                          | ● Astellas Pharma (DSMB)
● Janssen Pharmaceuticals (DSMB)                              | None           |                |
| Kaushal H. Shah          | Organizational Reviewer—ACEP/SAEM | The Mount Sinai Hospital—Associate Professor of Emergency Medicine | None       | None           | None                          | None             | None                                                      |                |
| Mike Silka               | Organizational Reviewer—PACES | Children’s Hospital Los Angeles—Professor of Pediatrics, Cardiology | None       | None           | None                          | None             | ● Defendant, SCD in CPVT patient, 2016                   |                |
| Sana M. Al-Khatib        | Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines | Duke Clinical Research Institute—Professor of Medicine | None       | None           | None                          | ● FDA*
● NHLBI*
● PCORI*
● VA Health System (DSMB)                                     | ● Elsevier*
● AHA                                                      | None           |
<p>| Kim K. Birtcher          | Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines | University of Houston College of Pharmacy—Clinical Professor | ● Jones &amp; Bartlett Learning | None           | None                          | None             | None                                                      |                |</p>
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Institution</th>
<th>None</th>
<th>None</th>
<th>None</th>
<th>None</th>
<th>None</th>
<th>None</th>
<th>None</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michele Brignole</td>
<td>Content Reviewer</td>
<td>Arrhythmologic Centre, Ospedali del Tigullio—Head of Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Hugh Calkins</td>
<td>Content Reviewer—ACC EP Section Leadership Council</td>
<td>Johns Hopkins Hospital—Professor of Medicine, Director of EP</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Coletta Barrett</td>
<td>Content Reviewer—Lay Reviewer</td>
<td>Our Lady of the Lake Regional Medical Center—Vice President</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Lin Yee Chen</td>
<td>Content Reviewer</td>
<td>University of Minnesota Medical School—Associate Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Andrew Epstein</td>
<td>Content Reviewer</td>
<td>University of Pennsylvania Hospital and the Veteran’s Administration Medical Center—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Susan Etheridge</td>
<td>Content Reviewer</td>
<td>University of Utah—Training Program Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Marci Farquhar-Snow</td>
<td>Content Reviewer</td>
<td>Mayo Clinic School of Health Sciences—Program Director, Cardiology Nurse Practitioner, Fellowship</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Samuel S. Gidding</td>
<td>Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines</td>
<td>Nemours/Alfred I. duPont Hospital for Children—Chief, Division of Pediatric Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Bulent Gorenek</td>
<td>Content Reviewer</td>
<td>Eskisehir Osmangazi University Cardiology Department—Chair</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Paul LeLorier</td>
<td>Content Reviewer</td>
<td>LSU Health Sciences Center—Associate Professor of Medicine and Neurology; EP Service—Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Reviewer</th>
<th>Representation</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick McBride</td>
<td>Content Reviewer</td>
<td>University of Wisconsin School of Medicine &amp; Public Health—Professor of Medicine and Family Medicine; Dean for Faculty Affairs—Associate; Prevention Cardiology—Associate Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Carlos Morillo</td>
<td>Content Reviewer</td>
<td>Cumming School of Medicine—Professor Department of Cardiac Sciences; University of Calgary—Section Chief Division of Cardiology, Libin Cardiovascular Institute</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Bayer HealthCare</td>
<td></td>
<td></td>
<td>• Biosense Webster</td>
<td></td>
<td>• Medtronic†</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Boehringer Ingelheim</td>
<td></td>
<td></td>
<td>• Canadian Institutes of Health Research†</td>
<td></td>
<td>• Merck</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Boston Scientific</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Pfizer</td>
<td>None</td>
</tr>
<tr>
<td>Carlos Morillo</td>
<td>Content Reviewer</td>
<td>University of Wisconsin School of Medicine &amp; Public Health—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mayo Clinic Division of Cardiovascular Disease—Professor of Medicine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Patrick McBride</td>
<td>Content Reviewer</td>
<td>University of Wisconsin School of Medicine &amp; Public Health—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Carlos Morillo</td>
<td>Content Reviewer</td>
<td>Cumming School of Medicine—Professor Department of Cardiac Sciences; University of Calgary—Section Chief Division of Cardiology, Libin Cardiovascular Institute</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Bayer HealthCare</td>
<td></td>
<td></td>
<td>• Biosense Webster</td>
<td></td>
<td>• Medtronic†</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Boehringer Ingelheim</td>
<td></td>
<td></td>
<td>• Canadian Institutes of Health Research†</td>
<td></td>
<td>• Merck</td>
<td>None</td>
</tr>
<tr>
<td>Richard Page</td>
<td>Content Reviewer</td>
<td>University of Wisconsin School of Medicine &amp; Public Health—Chair, Department of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Antonio Raviele</td>
<td>Content Reviewer</td>
<td>Alliance to Fight Atrial Fibrillation—President; Venice Arrhythmias—President</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Marwan Refaat</td>
<td>Content Reviewer</td>
<td>ACC EP Section Leadership Council—American University of Beirut—Faculty of Medicine and Medical Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Melissa Robinson</td>
<td>Content Reviewer</td>
<td>University of Washington—Assistant Professor of Medicine; Director, Ventricular Arrhythmia Program</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Paola Sandroni</td>
<td>Content Reviewer</td>
<td>Mayo Clinic—Professor of Neurology, Practice Chair of Neurology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Colette Seifer</td>
<td>Content Reviewer</td>
<td>University of Manitoba—Associate Professor, Section of Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Monica Solbiati</td>
<td>Content Reviewer</td>
<td>Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milano—Senior Physician</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Name</td>
<td>Content Reviewer</td>
<td>Affiliation</td>
<td>Relationships</td>
<td>Defendant, Fatal car accident caused by VVS patient, 3 trials in 2016*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richard Sutton</td>
<td>Content Reviewer</td>
<td>National Heart and Lung Institute, Imperial College London—Emeritus Professor</td>
<td>• Medtronic* • St. Jude Medical* • Boston Scientific* • Edwards Lifesciences* • Shire Pharmaceuticals • Boston Scientific • St. Jude Medical • AstraZeneca</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gaurav Upadhyay</td>
<td>Content Reviewer</td>
<td>University of Chicago—Assistant Professor of Medicine</td>
<td>• Biosense Webster None • Biotronik • Boston Scientific • Medtronic • St. Jude Medical • Zoll Medical</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paul Varosy</td>
<td>Content Reviewer</td>
<td>University of Colorado Hospital, Clinical Cardiac EP Training program—Associate Program Director; VA Eastern Colorado Healthcare System—Director of Cardiovascular EP</td>
<td>None None None</td>
<td>None None</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review, including those not deemed to be relevant to this document, at the time this document was under review. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. Please refer to http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

AAN = American Academy of Neurology; ACC = American College of Cardiology; ACEP = American College of Emergency Physicians; AHA = American Heart Association; ASA = American Stroke Association; DSMB = data safety monitoring board; CPVT = catecholaminergic polymorphic ventricular tachycardia; EP = electrophysiology; FDA = U.S. Food and Drug Administration; FH = familial hypercholesterolemia; HRS = Heart Rhythm Society; ICD = implantable cardioverter-defibrillator; JCE = Journal of Cardiovascular Electrophysiology; LSU = Louisiana State University; NHLBI = National Heart, Lung, and Blood Institute; PACE = Partners in Advanced Cardiac Evaluation; PACES = Pediatric and Congenital Electrophysiology Society; PCORI = Patient-Centered Outcomes Research Institute; PI = principal investigator; SADS = Sudden Arrhythmia Death Syndromes Foundation; SAEM = Society for Academic Emergency Medicine; SCAI = Society for Cardiovascular Angiography and Interventions; SCD = sudden cardiac death; VA = Veterans Affairs; VCU = Virginia Commonwealth University; and VVS = vasovagal syncope.

*Significant relationship.
†No financial benefit.
Appendix 3. Abbreviations

ACHD = adult congenital heart disease
ARVC = arrhythmogenic right ventricular cardiomyopathy
CPVT = catecholaminergic polymorphic ventricular tachycardia
ECG = electrocardiogram/electrocardiographic
EPS = electrophysiological study
GDMT = guideline-directed management and therapy
HCM = hypertrophic cardiomyopathy
ICD = implantable cardioverter-defibrillator
LQTS = long-QT syndrome
OH = orthostatic hypotension
RCT = randomized controlled trial
POTS = postural tachycardia syndrome
SCD = sudden cardiac death
VA = ventricular arrhythmia
VVS = vasovagal syncope